• RCC: deferred cytoreductive surgery improves survival in select patients

    Time to treatment failure also improved in real-world study.

  • RCC: PFS benefit of avelumab-axitinib combo confirmed

    Final PFS analysis of JAVELIN Renal 101 trial.

  • Renal cancer: atezolizumab tops sunitinib for QoL

    Less worsening of disease- and treatment-related symptoms with atezolizumab.

  • Large renal masses: partial and radical nephrectomy show similar survival, complications

    Partial approach retains renal function.

  • High-risk RCC: survival worsened with adjuvant targeted therapy

    Lymph node metastases are linked to poor OS with adjuvant therapy.

  • RCC: better QoL with front-line atezolizumab+bevacizumab

    Combination does not increase symptom or treatment burden vs sunitinib.

  • ESMO updates renal cancer guidelines

    New therapies/indications in renal cell carcinoma are listed.

  • ASCO-GU 2020 — Clear cell RCC: novel drug holds promise for advanced cases

    The drug is an oral hypoxia-inducible factor 2-alpha inhibitor.

  • RCC: immunotherapy rechallenge feasible in some patients

    50% of patients reported immune-related events with rechallenge, but manageable.

  • Systemic therapies refine surgical treatment of cancer

    ASCO lists notable 2019 studies in melanoma, renal, and pancreatic cancer.

  • ASCO-SITC 2020 — Metastatic RCC: combining ilixadencel with sunitinib improves responses

    Ilixadencel is an off-the-shelf cell-based immune primer.

  • Renal cancer drug combination not recommended by NICE

    Draft NICE decision on pembrolizumab with axitinib for untreated advanced renal cell carcinoma

  • High body mass index is tied to longer survival in renal cancer

    Patients with obesity have longer OS vs those with normal weight.

  • Metastatic renal cancer: sunitinib rechallenge feasible, safe

    Rechallenge can improve outcomes when later line novel therapies are not available.

  • Metastatic renal cancer: later-line tivozanib tops sorafenib for PFS

    Maintains PFS advantage in patients previously treated with checkpoint inhibitors.

  • Renal cancer: cryoablation tied to higher cancer-specific mortality in pT1 disease

    Guidelines do not recommend cryoablation.

  • Atezolizumab-bevacizumab combo active in variant histology or sarcomatoid renal cancer

    PD-L1-positive patients reported higher objective responses in phase 2.

  • Load more